Reminder of Class Action for Aldeyra Therapeutics Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 12 2026
0mins
Should l Buy ALDX?
Source: Globenewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics (NASDAQ: ALDX) securities between November 3, 2023, and March 16, 2026, to apply as lead plaintiffs by May 29, 2026, to potentially receive compensation without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Aldeyra made false and misleading statements regarding the inconsistent results of its drug candidate reproxalap clinical trials, which misrepresented the company's business and prospects, leading to investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its successful track record and resources in this field.
- Investor Guidance: Investors are advised to carefully select law firms with proven success records and avoid firms that merely act as intermediaries, ensuring effective legal representation and support in the class action process.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALDX
Wall Street analysts forecast ALDX stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.520
Low
9.00
Averages
9.50
High
10.00
Current: 1.520
Low
9.00
Averages
9.50
High
10.00
About ALDX
Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering therapies designed to treat immune-mediated and metabolic diseases. The Company's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder of Class Action for Aldeyra Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics (NASDAQ: ALDX) securities between November 3, 2023, and March 16, 2026, to apply as lead plaintiffs by May 29, 2026, to represent other investors in the class action.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Lawsuit Background: The lawsuit alleges that during the class period, Aldeyra's drug candidate reproxalap had inconsistent clinical trial results, leading to materially misleading statements about the company's business and prospects, causing investor losses.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Aldeyra Faces Class Action Lawsuit; Investors Encouraged to Contact Attorneys
- Class Action Filed: Bragar Eagel & Squire has initiated a class action lawsuit against Aldeyra in the U.S. District Court for Massachusetts on behalf of investors who purchased securities between November 3, 2023, and March 16, 2026, highlighting serious concerns regarding the company's operational integrity.
- Allegations of Misrepresentation: The lawsuit alleges that the defendants issued false and misleading statements and failed to disclose significant adverse facts about Aldeyra's business, particularly the inconsistency of reproxalap clinical trial results, which undermined investor confidence.
- Investor Rights Protection: Investors are urged to apply by May 29, 2026, to be appointed as lead plaintiffs, emphasizing the importance of safeguarding investor rights and the potential implications for future legal outcomes.
- Law Firm Credentials: Bragar Eagel & Squire is a nationally recognized law firm specializing in securities, derivative, and commercial litigation, demonstrating its expertise and commitment to protecting investor interests in complex legal matters.
See More
Aldeyra Therapeutics Faces Class Action for Securities Fraud
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Aldeyra Therapeutics (NASDAQ:ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between November 3, 2023, and March 16, 2026, with a deadline to contact the firm by May 29, 2026, for participation.
- False Statement Allegations: The complaint alleges that Aldeyra made false and misleading statements regarding the clinical trial results of its reproxalap drug candidate, with inconsistencies rendering the company's positive assertions unreliable, thus making its public statements materially misleading throughout the class period.
- Investor Losses: As the market learned the truth about Aldeyra, investors suffered damages, indicating significant deficiencies in the company's disclosure practices that could lead to stock price declines and erode investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations, encouraging affected investors to reach out to discuss their rights, demonstrating the firm's commitment to protecting shareholder interests.
See More
Aldeyra Faces Class Action Lawsuit, Stock Plummets 70.69%
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Aldeyra Therapeutics, alleging securities fraud by the company and certain officers, with investors needing to apply as Lead Plaintiff by May 29, 2026, indicating significant legal risks that could impact the company's reputation.
- Negative FDA Response: On March 17, 2026, Aldeyra received a Complete Response Letter from the FDA stating that its New Drug Application lacked sufficient evidence of efficacy, leading to regulatory challenges that may affect future drug approval plans.
- Stock Price Plunge: Following the FDA news, Aldeyra's stock price fell by $2.99, a staggering 70.69% drop to close at $1.24, reflecting market pessimism regarding the company's outlook and potentially undermining investor confidence.
- Law Firm's Reputation: Pomerantz LLP, a premier firm in securities class litigation with over 85 years of experience, focuses on protecting the rights of victims of securities fraud, suggesting that this lawsuit may attract broader legal scrutiny and attention.
See More
Reminder of Aldeyra Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics securities between November 3, 2023, and March 16, 2026, that they must apply to be lead plaintiff by May 29, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, minimizing the financial burden on investors while pursuing their claims.
- Lawsuit Background: The lawsuit alleges that Aldeyra made misleading statements regarding inconsistent results from clinical trials, which misled investors about the company's business and prospects, leading to financial losses and highlighting significant deficiencies in the company's disclosure practices.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Aldeyra Investors Alert: Class Action Deadline Approaches
- Class Action Deadline: Aldeyra Therapeutics reminds investors that May 29, 2026, is the deadline to apply for lead plaintiff status in a pending federal securities class action, with late applications being disqualified, which could affect investors' representation and decision-making in the litigation.
- Lawsuit Background: The lawsuit targets investors who purchased Aldeyra securities between November 3, 2023, and March 16, 2026, alleging that the company failed to disclose inconsistencies in clinical trial results for its drug candidate reproxalap, misleading investors about its efficacy.
- FDA Complete Response Letter: On March 17, 2026, Aldeyra received a Complete Response Letter from the FDA indicating a lack of substantial evidence supporting the drug's effectiveness in treating dry eye symptoms, raising further concerns among investors regarding the company's prospects.
- Stock Price Plunge Impact: Following this news, Aldeyra's stock price plummeted by 71%, from $4.23 on March 16, 2026, to $1.24, resulting in significant financial losses for investors and reflecting a severe decline in market confidence regarding the company's future.
See More
Reminder of Class Action for Aldeyra Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics (NASDAQ: ALDX) securities between November 3, 2023, and March 16, 2026, to apply as lead plaintiffs by May 29, 2026, to represent other investors in the class action.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Lawsuit Background: The lawsuit alleges that during the class period, Aldeyra's drug candidate reproxalap had inconsistent clinical trial results, leading to materially misleading statements about the company's business and prospects, causing investor losses.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Aldeyra Faces Class Action Lawsuit; Investors Encouraged to Contact Attorneys
- Class Action Filed: Bragar Eagel & Squire has initiated a class action lawsuit against Aldeyra in the U.S. District Court for Massachusetts on behalf of investors who purchased securities between November 3, 2023, and March 16, 2026, highlighting serious concerns regarding the company's operational integrity.
- Allegations of Misrepresentation: The lawsuit alleges that the defendants issued false and misleading statements and failed to disclose significant adverse facts about Aldeyra's business, particularly the inconsistency of reproxalap clinical trial results, which undermined investor confidence.
- Investor Rights Protection: Investors are urged to apply by May 29, 2026, to be appointed as lead plaintiffs, emphasizing the importance of safeguarding investor rights and the potential implications for future legal outcomes.
- Law Firm Credentials: Bragar Eagel & Squire is a nationally recognized law firm specializing in securities, derivative, and commercial litigation, demonstrating its expertise and commitment to protecting investor interests in complex legal matters.
See More
Aldeyra Therapeutics Faces Class Action for Securities Fraud
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Aldeyra Therapeutics (NASDAQ:ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between November 3, 2023, and March 16, 2026, with a deadline to contact the firm by May 29, 2026, for participation.
- False Statement Allegations: The complaint alleges that Aldeyra made false and misleading statements regarding the clinical trial results of its reproxalap drug candidate, with inconsistencies rendering the company's positive assertions unreliable, thus making its public statements materially misleading throughout the class period.
- Investor Losses: As the market learned the truth about Aldeyra, investors suffered damages, indicating significant deficiencies in the company's disclosure practices that could lead to stock price declines and erode investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations, encouraging affected investors to reach out to discuss their rights, demonstrating the firm's commitment to protecting shareholder interests.
See More
Aldeyra Faces Class Action Lawsuit, Stock Plummets 70.69%
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Aldeyra Therapeutics, alleging securities fraud by the company and certain officers, with investors needing to apply as Lead Plaintiff by May 29, 2026, indicating significant legal risks that could impact the company's reputation.
- Negative FDA Response: On March 17, 2026, Aldeyra received a Complete Response Letter from the FDA stating that its New Drug Application lacked sufficient evidence of efficacy, leading to regulatory challenges that may affect future drug approval plans.
- Stock Price Plunge: Following the FDA news, Aldeyra's stock price fell by $2.99, a staggering 70.69% drop to close at $1.24, reflecting market pessimism regarding the company's outlook and potentially undermining investor confidence.
- Law Firm's Reputation: Pomerantz LLP, a premier firm in securities class litigation with over 85 years of experience, focuses on protecting the rights of victims of securities fraud, suggesting that this lawsuit may attract broader legal scrutiny and attention.
See More
Reminder of Aldeyra Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics securities between November 3, 2023, and March 16, 2026, that they must apply to be lead plaintiff by May 29, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, minimizing the financial burden on investors while pursuing their claims.
- Lawsuit Background: The lawsuit alleges that Aldeyra made misleading statements regarding inconsistent results from clinical trials, which misled investors about the company's business and prospects, leading to financial losses and highlighting significant deficiencies in the company's disclosure practices.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Aldeyra Investors Alert: Class Action Deadline Approaches
- Class Action Deadline: Aldeyra Therapeutics reminds investors that May 29, 2026, is the deadline to apply for lead plaintiff status in a pending federal securities class action, with late applications being disqualified, which could affect investors' representation and decision-making in the litigation.
- Lawsuit Background: The lawsuit targets investors who purchased Aldeyra securities between November 3, 2023, and March 16, 2026, alleging that the company failed to disclose inconsistencies in clinical trial results for its drug candidate reproxalap, misleading investors about its efficacy.
- FDA Complete Response Letter: On March 17, 2026, Aldeyra received a Complete Response Letter from the FDA indicating a lack of substantial evidence supporting the drug's effectiveness in treating dry eye symptoms, raising further concerns among investors regarding the company's prospects.
- Stock Price Plunge Impact: Following this news, Aldeyra's stock price plummeted by 71%, from $4.23 on March 16, 2026, to $1.24, resulting in significant financial losses for investors and reflecting a severe decline in market confidence regarding the company's future.
See More
